RESEARCH PAPER
Synergy among oxcarbazepine , pregabalin and topiramate in the mouse maximal electroshockinduced seizure test – an isobolographic analysis
 
More details
Hide details
1
Department of Pathophysiology, Medical University, Lublin, Poland
2
Isobolographic Analysis Laboratory, Institute of Rural Health, Lublin, Poland
3
Institute of Rural Health, Isobolographic Analysis Laboratory, Poland
CORRESPONDING AUTHOR
Jarogniew J. Łuszczki   

Medical University of Lublin, Department of Pathophysiology, Department of Pathophysiology, 20-090, Lublin, Poland
 
J Pre Clin Clin Res. 2018;12(4):111–116
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Assessment of interactions among antiepileptic drugs (AEDs) during polytherapy is still a challenging issue for physicians and epileptologists worldwide. In spite of 25 currently licensed AEDs, there are no algorithms allowing a proper choice of these drugs to create combinations which would offer epileptic patients an efficacious therapy in the case of seizures refractory to monotherapeutic use of the AEDs. To characterize a type of interaction for a three-drug mixture of oxcarbazepine (OXC), pregabalin (PGB) and topiramate (TPM) in an experimental model of tonic-clonic seizures, an isobolographic analysis of interaction was applied.

Material and methods:
The anticonvulsant effects of the three-drug mixture of OXC, PGB and TPM with respect to suppression of tonic-clonic seizures in mice were assessed in the mouse maximal electroshock-induced seizure model. Type I isobolographic analysis was used to characterize the type of interactions among three AEDs. Potential acute adverse effects were evaluated in the chimney, passive avoidance and grip-strength tests.

Results:
The three-drug mixture of OXC, PGB and TPM exerted supra-additive (synergistic) interaction in the mouse maximal electroshock-induced seizure model. The combination of OXC, PGB and TPM did not produce any acute adverse effects in mice in the chimney, passive avoidance and grip-strength tests.

Conclusions:
The isobolographic synergy observed experimentally for the combination of OXC, PGB and TPM could be recommended to patients with drug-resistant epilepsy, if the results of this study were translated to clinical settings.

 
REFERENCES (46)
1.
Legge AW, Detyniecki K, Javed A, Hirsch LJ, Kato K, Buchsbaum R, et al. Comparative efficacy of unique antiepileptic drug regimens in focal epilepsy: An exploratory study. Epilepsy Res. 2018; 142: 73–80.
 
2.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018; 59(10): 1811–41.
 
3.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on new antiepileptic drugs and devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia. 2018; 59(10): 1842–66.
 
4.
Campos G, Fortuna A, Falcao A, Alves G. In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. Epilepsy Res. 2018; 146: 63–86.
 
5.
Santulli L, Coppola A, Balestrini S, Striano S. The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacol Res. 2016; 107: 211–9.
 
6.
Brodie MJ. Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide. Curr Neurol Neurosci Rep. 2016; 16(9): 82.
 
7.
Matsumura N, Nakaki T. Isobolographic analysis of the mechanisms of action of anticonvulsants from a combination effect. Eur J Pharmacol. 2014; 741: 237–46.
 
8.
Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000; 41(11): 1364–74.
 
9.
Gessner PK. Isobolographic analysis of interactions: an update on applications and utility. Toxicology. 1995; 105(2–3): 161–79.
 
10.
Berenbaum MC. What is synergy? Pharmacol Rev. 1989; 41(2): 93–141.
 
11.
Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002; 11(6): 349–51.
 
12.
Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations--have newer agents altered clinical outcomes? Epilepsy Res. 2012; 98(2–3): 194–8.
 
13.
Brodie MJ, Sills GJ. Combining antiepileptic drugs--rational polytherapy? Seizure. 2011; 20(5): 369–75.
 
14.
Luszczki JJ, Wlaz A, Karwan S, Florek-Luszczki M, Czuczwar SJ. Effects of WIN 55,212–2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. Eur J Pharmacol. 2013; 720(1–3): 247–54.
 
15.
Luszczki JJ, Antkiewicz-Michaluk L, Raszewski G, Czuczwar SJ. Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis. Epilepsy Res. 2010; 89(2–3): 207–19.
 
16.
Litchfield JT, Jr., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96(2): 99–113.
 
17.
Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953; 3(6): 285–90.
 
18.
Tallarida RJ. Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther. 2012; 342(1): 2–8.
 
19.
Luszczki JJ, Czuczwar SJ. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn Schmiedebergs Arch Pharmacol. 2006; 374(1): 51–64.
 
20.
Kondrat-Wróbel MW, Załuska K, Walczak A, Panasiuk-Poterek AN, Gut-Lepiech A, Wróblewska-Łuczka P, et al. Antagonistic interaction of lacosamide with carbamazepine and valproate in the tonic-clonic seizure model in mice. Health Probl Civil. 2018; 12(4): In press.
 
21.
Kondrat-Wrobel MW, Luszczki JJ. Interaction of three-drug combination of lacosamide, carbamazepine and phenobarbital in the mouse maximal electroshock-induced seizure model – an isobolographic analysis. Health Probl Civil. 2016; 10(1): 55–61.
 
22.
Zolkowska D, Zagaja M, Miziak B, Kondrat-Wrobel MW, Zaluska K, Florek-Luszczki M, et al. Isobolographic assessment of interactions between retigabine and phenytoin in the mouse maximal electroshock-induced seizure model and chimney test. Health Prob Civil. 2016; 10(4): 54–9.
 
23.
Luszczki JJ, Czuczwar SJ. Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. Eur Neuropsychopharmacol. 2005; 15(2): 133–42.
 
24.
Luszczki JJ, Swiader M, Parada-Turska J, Czuczwar SJ. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology. 2003; 28(10): 1817–30.
 
25.
Tallarida RJ. The interaction index: a measure of drug synergism. Pain. 2002; 98(1–2): 163–8.
 
26.
Meyer OA, Tilson HA, Byrd WC, Riley MT. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol. 1979; 1(3): 233–6.
 
27.
Kondrat-Wrobel MW, Luszczki JJ. Additive interaction for three-drug combination of carbamazepine, lacosamide and lamotrigine against maximal electroshock-induced seizures – a type I isobolographic analysis. Eur J Clin Exp Med. 2017; 15(4): 303–9.
 
28.
Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH, et al. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature. 1986; 321(6073): 864–6.
 
29.
Luszczki JJ, Wojcik-Cwikla J, Andres MM, Czuczwar SJ. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology. 2005; 30(5): 958–73.
 
30.
Luszczki JJ, Mazurkiewicz LP, Wroblewska-Luczka P, Wlaz A, Ossowska G, Szpringer M, et al. Combination of phenobarbital with phenytoin and pregabalin produces synergy in the mouse tonic-clonic seizure model: an isobolographic analysis. Epilepsy Res. 2018; 145: 116–22.
 
31.
Boissier JR, Tardy J, Diverres JC. Une nouvelle méthode simple pour explorer l’action «tranquillisante»: le test de la cheminée. [A new simple method to explore the “tranquillizing” action: the chimney test] Pharmacology. 1960; 3(1): 81–4 [French].
 
32.
Luszczki JJ, Wojda E, Raszewski G, Glowniak K, Czuczwar SJ. Influence of imperatorin on the anticonvulsant activity and acute adverse-effect profile of lamotrigine in maximal electroshock-induced seizures and chimney test in mice. Pharmacol Rep. 2008; 60(4): 566–73.
 
33.
Luszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharmacol. 2007; 375(2): 105–14.
 
34.
Tallarida RJ. Drug synergism and dose-effect data analysis. New York: Chapman and Hall/CRC 2000. 264 p.
 
35.
Tallarida RJ. Drug combinations: tests and analysis with isoboles. Curr Prot Pharmacol. 2016; 72: 9.19.19.
 
36.
Luszczki JJ. Isobolographic analysis of interaction for three-drug combination of carbamazepine, phenobarbital and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2016; 97(5–6): 259–64.
 
37.
Kondrat-Wrobel MW, Luszczki JJ. Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in the mouse tonic-clonic seizure model. Adv Clin Exp Med. 2018; 27(7): 881–6.
 
38.
Luszczki JJ, Filip D, Czuczwar SJ. Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. Epilepsy Res. 2010;91(2–3):166–75.
 
39.
Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia. 2004;45(8):895–907.
 
40.
Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Exp Rev Neurotherap. 2016;16(11):1263–77.
 
41.
Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008;8(4):345–52.
 
42.
Sitges M, Chiu LM, Reed RC. Effects of levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, oxcarbazepine, topiramate, vinpocetine and sertraline on presynaptic hippocampal Na(+) and Ca(2+) channels permeability. Neurochem Res. 2016;41(4):758–69.
 
43.
Angehagen M, Ben-Menachem E, Shank R, Ronnback L, Hansson E. Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J Neurochem. 2004;88(2):320–5.
 
44.
Gibbs JW, 3rd, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41(1):S10–6.
 
45.
Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003;23(18):7069–74.
 
46.
Loscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991;8(2):79–94.
 
eISSN:1898-7516
ISSN:1898-2395